High-throughput assay for virus entry and drug screening

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S008000, C435S029000, C435S032000

Reexamination Certificate

active

11036568

ABSTRACT:
The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins of the HIV Nef protein that would specifically associate with cell membranes to deliver the enzyme into viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.

REFERENCES:
patent: 2004/0096823 (2004-05-01), Greene et al.
patent: WO 02094874 (2002-11-01), None
Fields, Virology, 3rd Edition, p. 2722 (1996).
Cleveland et al., “A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion,” Journal of General Virology, 84, pp. 591-602 (2003).
Aiken, “Pseudotyping Human Immunodeficiency Virus Type 1 (HIV-1) by the Glycoprotein of Vesicular Stomatitis Virus Targets HIV-1 Entry to an Endocytic Pathway and Suppresses bothe the requirement for Nef and the sensitivity to Cyclosporin A,” Journal of Virology, vol. 71, No. 8, pp. 5871-5877 (1997).
Card et al., “Pseudorabies Virus Envelope Glycoprotein gl Influences both Neurotropism and Virulence during Infection of the Rat Visual system,” Journal of Virology, vol. 6, No. 5, pp. 3032-3041 (1992).
Davis et al., “Comparison of High Throughput Screening Technologies for Luminescence Cell-Based Reporter Screens,” Journal of Biomolecular Screening, vol. 7, No. 1, pp. 67-77 (2002).
He et al., “Use of a Novel Human Immunodeficiency Virus Type 1 Reporter Virus Expressing Human Placentel Alkaline Phosphatase to Detect an Alternative Viral Receptor,” Journal of Virology, vol. 69, No. 7, pp. 4587-4592 (1995).
Kovacs et al., “Firefly luciferase as a marker for herpesvirus (pseudorabies virus) replication in vitro and in vivo,” Journal of General Virology, 72, pp. 2999-3008 (1991).
Jons et al., “Green fluorescent protein expressed by recombinant pseudorabies virus as an in vivo marker for viral replication,” Journal of Virological Methods 66, pp. 283-292 (1997).
Pomeranz et al, Molecular Biology of Pseudorabies Virus: Impact on Neurovirology and Veterinary Medicine, vol. 69, No. 3, pp. 462-500 (2005).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

High-throughput assay for virus entry and drug screening does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with High-throughput assay for virus entry and drug screening, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High-throughput assay for virus entry and drug screening will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3931380

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.